Deals this week: Ultragenyx Pharmaceutical, Insmed, Harbour BioMed

26th January 2018 (Last Updated August 12th, 2019 10:39)

US-based biopharmaceutical company Ultragenyx Pharmaceutical Inc has announced a public offering of shares of its common stock to raise $175m.

US-based biopharmaceutical company Ultragenyx Pharmaceutical Inc has announced a public offering of shares of its common stock to raise $175m.

The company will grant underwriters a 30-day option to purchase additional shares worth $26.25m.

The company plans to use the proceeds for financing the commercialisation of Mepsevii, working capital, and other general corporate purposes.

Insmed Inc plans to raise $300m through an underwritten public offering of convertible senior notes due January 2025.

Underwriters will be granted a 30-day option to purchase additional notes worth $45m in principal amount.

The US-based biopharmaceutical company plans to use the proceeds to fund the clinical development and regulatory approval of amikacin liposome inhalation suspension (ALIS).

Chinese biopharmaceutical company Harbour BioMed has raised funds through a Series A+ financing round led by CDH Investments and Advantech Capital.

The proceeds will be used towards business growth and clinical programme development.

Adamas Pharmaceuticals Inc is planning to raise $85m through an underwritten public offering of shares of its common stock.

The US-based pharmaceutical company will grant underwriters a 30-day option to purchase additional shares worth $12.75m.

The proceeds are intended to be used to fund the advancement of research and development programmes and towards working capital and general corporate purposes.

Ablynx NV has completed the private placement of 218,998 new shares priced at €7.72 ($9.43) a share to raise €1.69m ($2.06m).

Based in Belgium, Ablynx is a biopharmaceutical company involved in the development of nanobodies and proprietary therapeutic proteins.

"The company will also grant the underwriters a 30-day option to buy 645,000 additional shares of its common stock at the public offer price."

US-based clinical-stage biopharmaceutical company Athenex Inc has issued an underwritten public offering of 4.3 million shares of its common stock priced at $15.97 a share to raise $68.67m.

The company will also grant the underwriters a 30-day option to buy 645,000 additional shares of its common stock at the public offer price.

Athenex will use the proceeds towards the development and regulatory activities of its orascovery and Src Kinase Inhibition product candidates, working capital and general corporate purposes.

UK-based clinical-stage biotechnology company Tiziana Life Sciences Plc has completed the private placement of 66,667 new ordinary shares priced at £1.50 ($2.08) a share to raise £100,000 ($140,000).

Each share has a warrant attached that enables the holder to subscribe to one new ordinary share at an exercise price of £1.60 ($2.22) a share until 22 January 2024.

Histogenics Corp has issued an underwritten registered direct offering of 2,340,430 shares of its common stock priced at $2.35 a share to raise $5.5m.

The company will also grant the underwriters a 30-day option to buy 351,064 additional shares of common stock.

Based in the US, Histogenics Corp is involved in the development of restorative cell therapies.

The company will use the proceeds towards working capital and general corporate purposes.

Selvita SA plans to offer 2.2 million new series H shares priced at PLN63.63 ($18.67) a share to raise PLN140m ($41.09m).

The Polish biotechnology company will use the proceeds to execute its 2017-2021 development strategy.